A
Alcista
Alcista · 25%CADL
$8.02
Precio del escenario
$8.030
-0.336 (-4.18%)Al cierre
Loading chart…
- Máximo
- 8.330
- Apertura
- 8.330
- Precio medio ponderado por volumen
- 8.09
- Volumen
- 1.18M
- Capitalización
- 175.26M
- Mínimo
- 7.905
- Importe
- 9.58M
- EV/EBITDA, TTM
- 0.00
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Análisis de IA of Candel Therapeutics Inc (CADL)
MantenerCandel Therapeutics is currently a hold. The stock is priced at $8.19, significantly below the analyst price target of $18, indicating potential upside. However, the RSI is at a very low 10.741, suggesting the stock is oversold, but this also raises concerns about further declines. The company has reported substantial net losses, with a net income of -38905000 USD in Q2 2026, which poses a risk to recovery.
Métricas de valoración
El PER previsto actual de Candel Therapeutics Inc (CADL) es 43.48, frente a su media de 5 años de 2.93.
Escenarios de precio de Alphio AI para CADL
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con CADL en cartera
Cronología de eventos
Noticias
7.509-17stocktwitsFed Raises Rates by 25 Basis Points, Markets React Positively
5.009-11NASDAQ.COMCandel Therapeutics Appoints New Board Member
8.508-28NASDAQ.COMCandel Therapeutics Achieves Significant Clinical Milestones
8.508-13stocktwitsCandel Advances Biologics License Application for Prostate Cancer Therapy
8.508-13NewsfilterCandel Plans to Submit Biologics License Application for Aglatimagene
Preguntas frecuentes sobre CADL, respondidas por Alphio AI
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Candel Therapeutics is currently a hold. The stock is priced at $8.19, significantly below the analyst price target of $18, indicating potential upside. However, the RSI is at a very low 10.741, suggesting the stock is oversold, but this also raises concerns about further declines. The company has reported substantial net losses, with a net income of -38905000 USD in Q2 2026, which poses a risk to recovery.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.